Manganese produce a parkinsonism-like illness characterized by movement abnormalities. This condition is not responsive to typical therapies used in the treatment of PD, suggesting an alternative pathway than the typical dopaminergic loss within the substantia nigra. Manganese may accumulate in the basal ganglia, leading to the abnormal movements. A mutation of the SLC30A10 gene, a manganese efflux transporter necessary for decreasing intracellular Mn, has been linked with the development of this Parkinsonism-like disease. The Lewy bodies typical to PD are not seen in Mn-induced parkinsonism. Animal experiments have given the opportunity to examine the consequences of manganese overexposure under controlled conditions.
Manganese(II) carbonate Manganese(II) carbonate Manganese carbonate is a compound with the chemical formula MnCO. Manganese carbonate occurs naturally as the mineral rhodochrosite but it is typically produced industrially. It is a pale pink, water-insoluble solid. Approximately 20,000 metric tonnes were produced in 2005. MnCO adopts a structure like calcite, consisting of manganese(II) ions in an octahedral coordination geometry. Treatment of aqueous solutions of manganese(II) nitrate with ammonia and carbon dioxide leads to precipitation of this faintly pink solid. The side product, ammonium nitrate is used as fertilizer. The carbonate is insoluble in water but, like most carbonates, hydrolyses upon treatment with acids